Código QR (código de barras bidimensional)

Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system

IntroductionIn 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (MS). Differently from ocrelizumab, that is adminis...

ver descrição completa

Na minha lista:
Principais autores: Cristina Scavone, Antonietta Anatriello, Isabella Baccari, Andrea Cantone, Daniele Di Giulio Cesare, Francesca Futura Bernardi, Ornella Moreggia, Valerio Liguori, Vincenzo Andreone, Giorgia Teresa Maniscalco, Annalisa Capuano
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-06-01
coleção:Frontiers in Neurology
Assuntos:
Eudravigilance
infusion reactions
injective reactions
multiple sclerosis
ocrelizumab
ofatumumab
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fneur.2024.1383910/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados